首页>
外国专利>
Ixekizumab and its pharmaceutically acceptable derivatives (TALTZ)
Ixekizumab and its pharmaceutically acceptable derivatives (TALTZ)
展开▼
机译:伊克珠单抗及其药学上可接受的衍生物(TALTZ)
展开▼
页面导航
摘要
著录项
相似文献
摘要
Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
展开▼